Lysosomal storage disorders: cross-border specialty drug access for international patients

Quick orientation

Lysosomal storage disorders collectively affect approximately 1 in 5,000 to 7,000 live births. Individually, most are ultra-rare.

Typical age of onset. Most forms present in infancy or childhood; some have adult-onset forms.

Severity tiers. Severity varies widely by disorder and genotype. Many forms are progressive and life-limiting without enzyme replacement, substrate reduction, or gene therapy.

Why specialty drugs for Lysosomal storage disorders are hard to access internationally

Enzyme replacement therapies and substrate reduction therapies are available for several LSDs but are not always registered locally. Newer approvals such as Lenmeldy for metachromatic leukodystrophy require qualified centers for cell-based gene therapy. Pediatric supply continuity across borders is a particular challenge.

Treatments approved by the FDA

• Elfabrio (pegunigalsidase alfa-iwxj) — FDA approval: 2023. Mechanism: Pegylated enzyme replacement for Fabry disease. Route: Intravenous infusion every 2 weeks. US WAC ballpark: Approximately USD 320,000 per year. Country pricing: UAE · Oman.
• Pombiliti (cipaglucosidase alfa-atga) — FDA approval: 2023. Mechanism: Enzyme replacement for late-onset Pompe disease. Route: Intravenous infusion every 2 weeks. US WAC ballpark: Approximately USD 650,000 per year. Country pricing: Saudi Arabia · Egypt · Bahrain.
• Lenmeldy (atidarsagene autotemcel) — FDA approval: 2024. Mechanism: Autologous ex vivo gene therapy for metachromatic leukodystrophy. Route: One-time intravenous infusion of modified autologous cells. US WAC ballpark: Approximately USD 4.25 million one-time. Country pricing: UAE · Saudi Arabia · Bahrain · Oman · Lebanon.
• Aqneursa (levacetylleucine) — FDA approval: 2024. Mechanism: Modified amino acid for Niemann-Pick disease type C. Route: Oral three times daily. US WAC ballpark: Approximately USD 295,000 per year. Country pricing: Saudi Arabia · India · Jordan · Bahrain.
• Miplyffa (arimoclomol) — FDA approval: 2024. Mechanism: Heat shock protein amplifier for Niemann-Pick disease type C. Route: Oral three times daily. US WAC ballpark: Approximately USD 400,000 per year.
• Galafold (migalastat) — FDA approval: 2018. Mechanism: Pharmacological chaperone for Fabry disease (amenable variants). Route: Oral every other day. US WAC ballpark: Approximately USD 350,000 per year.
• Xenpozyme (olipudase alfa) — FDA approval: 2022. Mechanism: Acid sphingomyelinase replacement for ASMD. Route: Intravenous infusion every 2 weeks. US WAC ballpark: Approximately USD 500,000 per year.
• Nexviazyme (avalglucosidase alfa) — FDA approval: 2021. Mechanism: Enzyme replacement for late-onset Pompe disease. Route: Intravenous infusion every 2 weeks. US WAC ballpark: Approximately USD 750,000 per year. Country pricing: Bahrain · Lebanon.

Cross-border pathways used for Lysosomal storage disorders

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Rare Pediatric Disease
• Medical Tourism Access

What your physician needs to know

• Confirm specific disorder by enzyme assay and genotype.
• Document organ involvement and baseline functional status.
• Many ERT products require infusion access; some allow home infusion after stable tolerance.
• Anti-drug antibody monitoring may be required.
• Pediatric metabolic specialist co-management is essential.

Common questions

Which LSD products does Reserve Meds support?

We support all FDA-approved ERTs and substrate reduction therapies that can be cross-border-shipped. Cell-based gene therapies are supported via medical-tourism access.

Are ERTs available locally?

Some are; some are not. Older agents are more widely registered. We confirm by destination.

Can my child receive home infusion?

Many ERT products allow home infusion after stable hospital initiation. Your treating center decides.

How long does shipment take?

Five to fifteen business days for biologic products; cell therapies require travel.

What documents are required?

Enzyme assay, genetic confirmation, treating physician's prescription, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Lysosomal storage disorders, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Lysosomal storage disorders

Reserved for you.